$20.64
+0.08
(+0.39%)▲
Insights on Fulgent Genetics Inc
Revenue is down for the last 2 quarters, 84.68M → 70.50M (in $), with an average decrease of 16.8% per quarter
Netprofit is down for the last 3 quarters, -11.22M → -128.14M (in $), with an average decrease of 447.2% per quarter
In the last 1 year, Iqvia Holdings Inc. has given 17.6% return, outperforming this stock by 48.8%
In the last 3 years, Thermo Fisher Scientific, Inc. has given 2.7% return, outperforming this stock by 78.4%
0.63%
Downside
Day's Volatility :2.52%
Upside
1.9%
3.68%
Downside
52 Weeks Volatility :54.91%
Upside
53.19%
Period | Fulgent Genetics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -19.88% | 1.9% | 0.0% |
6 Months | -18.45% | 10.7% | 0.0% |
1 Year | -31.22% | 4.6% | -1.1% |
3 Years | -76.47% | 14.2% | -22.1% |
Market Capitalization | 601.3M |
Book Value | $38.31 |
Earnings Per Share (EPS) | -5.63 |
PEG Ratio | 1.32 |
Wall Street Target Price | 26.67 |
Profit Margin | -58.03% |
Operating Margin TTM | -47.5% |
Return On Assets TTM | -3.47% |
Return On Equity TTM | -14.58% |
Revenue TTM | 289.2M |
Revenue Per Share TTM | 9.71 |
Quarterly Revenue Growth YOY | 4.1000000000000005% |
Gross Profit TTM | 366.9M |
EBITDA | -46.6M |
Diluted Eps TTM | -5.63 |
Quarterly Earnings Growth YOY | -0.99 |
EPS Estimate Current Year | -1.06 |
EPS Estimate Next Year | -0.76 |
EPS Estimate Current Quarter | -0.29 |
EPS Estimate Next Quarter | -0.23 |
What analysts predicted
Upside of 29.22%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 21.4M | ↑ 14.03% |
Net Income | -4.5M | ↑ 68.7% |
Net Profit Margin | -21.02% | ↓ 6.81% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 32.5M | ↑ 52.31% |
Net Income | 366.0K | ↓ 108.15% |
Net Profit Margin | 1.13% | ↑ 22.15% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 421.7M | ↑ 1196.46% |
Net Income | 214.3M | ↑ 58454.64% |
Net Profit Margin | 50.82% | ↑ 49.69% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 992.6M | ↑ 135.37% |
Net Income | 104.3M | ↓ 51.31% |
Net Profit Margin | 10.51% | ↓ 40.31% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 619.0M | ↓ 37.64% |
Net Income | 143.4M | ↑ 37.44% |
Net Profit Margin | 23.17% | ↑ 12.66% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 289.2M | ↓ 53.27% |
Net Income | -167.8M | ↓ 217.03% |
Net Profit Margin | -58.03% | ↓ 81.2% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 105.7M | ↓ 15.71% |
Net Income | 1.3M | ↓ 88.36% |
Net Profit Margin | 1.27% | ↓ 7.93% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 67.7M | ↓ 35.92% |
Net Income | -24.1M | ↓ 1892.7% |
Net Profit Margin | -35.56% | ↓ 36.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 66.2M | ↓ 2.27% |
Net Income | -15.8M | ↓ 34.17% |
Net Profit Margin | -23.95% | ↑ 11.61% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 67.9M | ↑ 2.55% |
Net Income | -11.2M | ↓ 29.15% |
Net Profit Margin | -16.55% | ↑ 7.4% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 84.7M | ↑ 24.81% |
Net Income | -13.1M | ↑ 16.72% |
Net Profit Margin | -15.48% | ↑ 1.07% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 70.5M | ↓ 16.75% |
Net Income | -128.1M | ↑ 877.71% |
Net Profit Margin | -181.76% | ↓ 166.28% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 55.0M | ↓ 3.4% |
Total Liabilities | 2.7M | ↓ 6.15% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 88.8M | ↑ 61.33% |
Total Liabilities | 6.0M | ↑ 117.81% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 700.5M | ↑ 689.2% |
Total Liabilities | 131.1M | ↑ 2092.24% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↑ 82.55% |
Total Liabilities | 112.8M | ↓ 13.91% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↑ 8.39% |
Total Liabilities | 116.2M | ↑ 2.96% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.3B | ↓ 8.15% |
Total Liabilities | 139.8M | ↑ 20.35% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↓ 3.82% |
Total Liabilities | 124.4M | ↓ 17.59% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↓ 1.4% |
Total Liabilities | 116.2M | ↓ 6.6% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↓ 0.67% |
Total Liabilities | 107.8M | ↓ 7.17% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↓ 1.61% |
Total Liabilities | 91.3M | ↓ 15.39% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.4B | ↑ 0.28% |
Total Liabilities | 96.6M | ↑ 5.82% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 6.28% |
Total Liabilities | 139.8M | ↑ 44.8% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -675.0K | ↓ 150.71% |
Investing Cash Flow | 950.0K | ↓ 146.36% |
Financing Cash Flow | 15.0K | ↓ 101.95% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.5M | ↓ 917.33% |
Investing Cash Flow | -29.0M | ↓ 3157.47% |
Financing Cash Flow | 28.8M | ↑ 191733.33% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 140.6M | ↑ 2448.99% |
Investing Cash Flow | -326.4M | ↑ 1023.87% |
Financing Cash Flow | 261.3M | ↑ 807.91% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 538.6M | ↑ 282.98% |
Investing Cash Flow | -546.5M | ↑ 67.43% |
Financing Cash Flow | 85.4M | ↓ 67.31% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 253.5M | ↓ 52.93% |
Investing Cash Flow | -261.3M | ↓ 52.19% |
Financing Cash Flow | -77.1M | ↓ 190.32% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 20.8M | ↑ 86.73% |
Investing Cash Flow | 44.3M | ↓ 120.73% |
Financing Cash Flow | -35.5M | ↑ 217.99% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 33.2M | ↑ 59.83% |
Investing Cash Flow | -92.6M | ↓ 309.08% |
Financing Cash Flow | -29.6M | ↓ 16.55% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -7.9M | ↓ 123.81% |
Investing Cash Flow | -4.4M | ↓ 95.3% |
Financing Cash Flow | -1.1M | ↓ 96.28% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 9.7M | ↓ 223.14% |
Investing Cash Flow | -1.1M | ↓ 74.83% |
Financing Cash Flow | -16.3M | ↑ 1376.75% |
Sell
Neutral
Buy
Fulgent Genetics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Fulgent Genetics Inc | -7.14% | -18.45% | -31.22% | -76.47% | 185.56% |
Danaher Corp. | 2.14% | 28.59% | -0.49% | -1.93% | 95.75% |
Idexx Laboratories, Inc. | -6.78% | 14.63% | -1.95% | -11.57% | 119.88% |
Agilent Technologies Inc. | -4.37% | 31.77% | 0.52% | 1.35% | 83.67% |
Thermo Fisher Scientific, Inc. | 0.18% | 25.39% | 0.05% | 16.3% | 119.68% |
Iqvia Holdings Inc. | -4.12% | 27.82% | 17.55% | 2.23% | 75.73% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics Inc | 7.49 | NA | 1.32 | -1.06 | -0.15 | -0.03 | NA | 38.31 |
Danaher Corp. | 41.86 | 41.86 | 3.13 | 7.62 | 0.08 | 0.04 | 0.0 | 72.36 |
Idexx Laboratories, Inc. | 47.62 | 47.62 | 4.75 | 11.13 | 0.81 | 0.23 | NA | 17.88 |
Agilent Technologies Inc. | 32.04 | 32.04 | 2.7 | 5.5 | 0.21 | 0.08 | 0.01 | 21.12 |
Thermo Fisher Scientific, Inc. | 35.47 | 35.47 | 2.81 | 21.55 | 0.13 | 0.05 | 0.0 | 120.87 |
Iqvia Holdings Inc. | 32.69 | 32.69 | 1.33 | 11.11 | 0.23 | 0.05 | NA | 33.67 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Fulgent Genetics Inc | Buy | $601.3M | 185.56% | 7.49 | -58.03% |
Danaher Corp. | Buy | $174.8B | 95.75% | 41.86 | 19.94% |
Idexx Laboratories, Inc. | Buy | $39.8B | 119.88% | 47.62 | 23.08% |
Agilent Technologies Inc. | Buy | $39.2B | 83.67% | 32.04 | 18.35% |
Thermo Fisher Scientific, Inc. | Buy | $209.3B | 119.68% | 35.47 | 13.99% |
Iqvia Holdings Inc. | Buy | $43.4B | 75.73% | 32.69 | 9.06% |
BlackRock Inc
Dimensional Fund Advisors, Inc.
Vanguard Group Inc
State Street Corporation
Geode Capital Management, LLC
Park West Asset Management LLC
mission developing flexible and affordable genetic testing that improves the everyday lives of those around us. founded in 2011, fulgent began with two simple ideas; flexibility and affordability. today, we strive to create the most effective and wide ranging tests on the market. all of this is done in the pursuit of bettering the everyday lives of our customers. we shine brightest when meaningful relationships, passion, and purpose come together. why fulgent? we are committed to working side-by-side with every one of our clients. this is essential to a strong and successful relationship and is our core way of doing business. we have collaborated with some of the top clinicians in our field who have assisted us in creating our panels, report formatting, and improvements to our website. our approach has always been simple: provide testing based on the specific needs of clinicians and their patients. customer support our support philosophy has always been simple: answer our client's ques
Organization | Fulgent Genetics Inc |
Employees | 1184 |
CEO | Mr. Ming Hsieh |
Industry | Health Services |